中原医刊
中原醫刊
중원의간
CENTRAL PLAINS MEDICAL JOURNAL
2008年
2期
15-17
,共3页
秦长岭%李汉贤%赵晓春%欧阳军%曾郁
秦長嶺%李漢賢%趙曉春%歐暘軍%曾鬱
진장령%리한현%조효춘%구양군%증욱
乳腺癌%前哨淋巴结%注射法
乳腺癌%前哨淋巴結%註射法
유선암%전초림파결%주사법
Breast cancer%Sentinel lymph node%Injection
目的 比较美蓝乳晕下(SA)注射法与皮内(ID)注射法行乳腺癌前哨淋巴结活检(SLNB)的检出率、灵敏度.方法 将62例T1、T2期乳腺癌患者按注射部位不同以1:1随机分为SA组和ID组.硬膜外麻醉后,取1%美蓝(MB)5 ml注入乳晕四周皮下或肿瘤上方对应皮肤周围,注射后10 min取腋窝切口,切开腋筋膜解剖腋窝,循蓝染淋巴管寻找蓝染淋巴结(即SLN),行SLNB,然后实施腋窝淋巴结清扫(ALND).所有标本送病检.结果 SA组SLNB检出率为87.1%(27/31),灵敏度为85.7%(6/7),准确率为96.3%(26/27),假阴性率为14.3%(1/7).ID组SLNB检出率为93.5%(29/31),灵敏度为87.5%(7/8),准确度为96.6%(28/29),假阴性率为12.5%(1/8).两组间差异无统计学意义(P>0.05).结论 采用ID法行乳腺癌SLNB的准确率和灵敏度与SA法相当,但尚需要大样本随机研究做进一步证实.
目的 比較美藍乳暈下(SA)註射法與皮內(ID)註射法行乳腺癌前哨淋巴結活檢(SLNB)的檢齣率、靈敏度.方法 將62例T1、T2期乳腺癌患者按註射部位不同以1:1隨機分為SA組和ID組.硬膜外痳醉後,取1%美藍(MB)5 ml註入乳暈四週皮下或腫瘤上方對應皮膚週圍,註射後10 min取腋窩切口,切開腋觔膜解剖腋窩,循藍染淋巴管尋找藍染淋巴結(即SLN),行SLNB,然後實施腋窩淋巴結清掃(ALND).所有標本送病檢.結果 SA組SLNB檢齣率為87.1%(27/31),靈敏度為85.7%(6/7),準確率為96.3%(26/27),假陰性率為14.3%(1/7).ID組SLNB檢齣率為93.5%(29/31),靈敏度為87.5%(7/8),準確度為96.6%(28/29),假陰性率為12.5%(1/8).兩組間差異無統計學意義(P>0.05).結論 採用ID法行乳腺癌SLNB的準確率和靈敏度與SA法相噹,但尚需要大樣本隨機研究做進一步證實.
목적 비교미람유훈하(SA)주사법여피내(ID)주사법행유선암전초림파결활검(SLNB)적검출솔、령민도.방법 장62례T1、T2기유선암환자안주사부위불동이1:1수궤분위SA조화ID조.경막외마취후,취1%미람(MB)5 ml주입유훈사주피하혹종류상방대응피부주위,주사후10 min취액와절구,절개액근막해부액와,순람염림파관심조람염림파결(즉SLN),행SLNB,연후실시액와림파결청소(ALND).소유표본송병검.결과 SA조SLNB검출솔위87.1%(27/31),령민도위85.7%(6/7),준학솔위96.3%(26/27),가음성솔위14.3%(1/7).ID조SLNB검출솔위93.5%(29/31),령민도위87.5%(7/8),준학도위96.6%(28/29),가음성솔위12.5%(1/8).량조간차이무통계학의의(P>0.05).결론 채용ID법행유선암SLNB적준학솔화령민도여SA법상당,단상수요대양본수궤연구주진일보증실.
Objective To compare the accuracy and success rate of two techniques,intradermal injection of methylene blue versus subareolar injection in sentinel lymph node localization in the management of early breast cancer. Methods Sixty -two patients with clinical stage T1-T2, No breast cancer who were eligible for the study were randomized in a 1 : 1 manner to one of two injection routes for methylene blue (MB) : ID,SA. Immediately after the induction of epidural anesthesia, patients were injected with 5 ml of 1% MB in the SA location or the skin overlying the tumor. Then 10 minutes later, the blue SLNs were identified by searching for the blue lymphatic vessel and the blue lymph node via a small axillary incision, followed by sentinel lymph node biopsy and axillary dissection. All removed nodes were sent for pathological examination, with the sentinel node tagged separately from other nodes. Results The sentinel lymph node was identified in 27/31 (87.1% ) SA and 29/31 (93.5%) ID ( overall P = 0. 668 ). SLNB accuracy, sensitivity, false - negative rate were 96. 3% (26/27),85.7% (6/7), 14. 3% (1/7) ,87.5% (7/8) ,96. 6% (28/29), 12. 5% ( 1/8 ) for SA and ID,respectively. Conclusion Sentinel lymph node localization by injeeton of methylene blue subareolarly or intradermally predicts the axillary lymph node status in early breast cancer with comparable success rates, accuracy. A larger randomized trial is needed to confirm these findings.